CO6680653A2 - Fabricación del inhibidor inter-alfa(iaip) a partir de plasma - Google Patents

Fabricación del inhibidor inter-alfa(iaip) a partir de plasma

Info

Publication number
CO6680653A2
CO6680653A2 CO13035387A CO13035387A CO6680653A2 CO 6680653 A2 CO6680653 A2 CO 6680653A2 CO 13035387 A CO13035387 A CO 13035387A CO 13035387 A CO13035387 A CO 13035387A CO 6680653 A2 CO6680653 A2 CO 6680653A2
Authority
CO
Colombia
Prior art keywords
lalp
precipitate
fraction
plasma
manufacture
Prior art date
Application number
CO13035387A
Other languages
English (en)
Spanish (es)
Inventor
Shawn F Bairstow
Jennifer Hutsell
Sindhu Ramachandran
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of CO6680653A2 publication Critical patent/CO6680653A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/30Extraction; Separation; Purification by precipitation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CO13035387A 2010-07-23 2013-02-21 Fabricación del inhibidor inter-alfa(iaip) a partir de plasma CO6680653A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36733110P 2010-07-23 2010-07-23

Publications (1)

Publication Number Publication Date
CO6680653A2 true CO6680653A2 (es) 2013-05-31

Family

ID=44534634

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13035387A CO6680653A2 (es) 2010-07-23 2013-02-21 Fabricación del inhibidor inter-alfa(iaip) a partir de plasma

Country Status (14)

Country Link
US (2) US8841248B2 (https=)
EP (1) EP2596014B1 (https=)
JP (1) JP5830096B2 (https=)
KR (1) KR20130093607A (https=)
CN (1) CN103119058A (https=)
AU (1) AU2011280907B2 (https=)
BR (1) BR112013001753A2 (https=)
CA (1) CA2806645A1 (https=)
CO (1) CO6680653A2 (https=)
EA (1) EA201390156A1 (https=)
ES (1) ES2717177T3 (https=)
MX (1) MX2013000958A (https=)
SG (1) SG187599A1 (https=)
WO (1) WO2012012773A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3087991A1 (en) 2003-11-08 2016-11-02 Prothera Biologics Composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
CN106928346B (zh) 2008-05-28 2021-09-07 普罗瑟拉生物公司 来自血液的间-α抑制物蛋白的制备和组合物
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
SG187599A1 (en) 2010-07-23 2013-03-28 Baxter Int Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma
TWI629283B (zh) 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之i-iv-1部分沉澱
WO2014039987A2 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US20140206844A1 (en) * 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
WO2017062536A2 (en) * 2015-10-06 2017-04-13 Kieu Hoang A method of manfacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
WO2018053029A1 (en) 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
BR112019022358A2 (pt) 2017-04-25 2020-05-19 Prothera Biologics, Inc. métodos para quantificar proteínas inibidoras inter-alfa
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
US20210393750A1 (en) * 2018-10-24 2021-12-23 Prothera Biologics, Inc. Inter-alpha inhibitor proteins and methods of use thereof
CN109867717A (zh) * 2019-04-01 2019-06-11 山西瑞亚力生物技术有限公司 一种血浆中α1微球蛋白的提取方法
EP3994165A1 (en) * 2019-07-04 2022-05-11 CSL Behring GmbH Process for purifying c1-inh
EP4126930A1 (en) * 2020-03-31 2023-02-08 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation from c-1 inhibitor depleted plasma
CN116322920A (zh) * 2020-11-09 2023-06-23 武田药品工业株式会社 使用氧化硅吸附从血浆中纯化fviii
US20230416342A1 (en) 2020-11-16 2023-12-28 Prothera Biologics, Inc. Methods for purifying inter-alpha inhibitor proteins
US20250281530A1 (en) * 2022-05-02 2025-09-11 Takeda Pharmaceutical Company Limited Methods of preparing cohn pool concentrate from blood plasma through ultrafiltration

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) * 1942-02-09 1945-12-04 Research Corp Protein product and process
DK166763B1 (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US5055447A (en) * 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
FR2711371B1 (fr) * 1993-10-18 1995-12-29 Aetsrn Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu.
ATE211486T1 (de) * 1995-09-22 2002-01-15 Zlb Bioplasma Ag Verfahren zur gewinnung von immunglobulinen aus fraktionen, die bei der fraktionierung von menschlichem blutplasma entstehen
EP1326893A2 (de) 2000-10-13 2003-07-16 Octapharma AG Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung
EP3087991A1 (en) * 2003-11-08 2016-11-02 Prothera Biologics Composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
CN101160133B (zh) * 2004-11-05 2013-01-09 普罗瑟拉生物公司 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
ES2595059T3 (es) 2007-03-20 2016-12-27 Csl Behring Gmbh Métodos para la producción a escala industrial de preparados terapéuticos del Factor H del complemento a partir de plasma humano
CN106928346B (zh) * 2008-05-28 2021-09-07 普罗瑟拉生物公司 来自血液的间-α抑制物蛋白的制备和组合物
US8304524B2 (en) * 2009-07-23 2012-11-06 Baxter International Inc. Manufacture of factor H (FH) and FH-derivatives from plasma
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
SG187599A1 (en) 2010-07-23 2013-03-28 Baxter Int Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma

Also Published As

Publication number Publication date
EP2596014B1 (en) 2018-11-28
US8841248B2 (en) 2014-09-23
CA2806645A1 (en) 2012-01-26
ES2717177T3 (es) 2019-06-19
KR20130093607A (ko) 2013-08-22
AU2011280907A1 (en) 2013-02-07
MX2013000958A (es) 2013-11-20
AU2011280907B2 (en) 2016-02-04
US20120053113A1 (en) 2012-03-01
EA201390156A1 (ru) 2014-01-30
JP2013535468A (ja) 2013-09-12
EP2596014A1 (en) 2013-05-29
JP5830096B2 (ja) 2015-12-09
US9505814B2 (en) 2016-11-29
SG187599A1 (en) 2013-03-28
CN103119058A (zh) 2013-05-22
US20150045538A1 (en) 2015-02-12
BR112013001753A2 (pt) 2016-05-31
WO2012012773A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
CO6680653A2 (es) Fabricación del inhibidor inter-alfa(iaip) a partir de plasma
PH12014502524B1 (en) Carboxylic acid compounds
AT516600A5 (de) Herstellung von faktor h (fh) und fh-derivaten aus plasma
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
BRPI0909040A8 (pt) Derivados de azetidina e ciclobutano, seus usos, e composição
AR076800A1 (es) Metodo para producir una preparacion de inmunoglobulina con un alto rendimiento
MX378354B (es) Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
PE20171108A1 (es) Metodos de purificacion de cannabinoides, composiciones y kits de los mismos
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
EA201301181A1 (ru) Триазолопиридины
AR081427A1 (es) Metodo para preparar anticuerpos con propiedades mejoradas
MX351467B (es) Nuevos derivados de fosfato de isoquinolinilcarbonilfenil indolizinilo o fosfato de isoquinolinilcarbonilfenil pirrolilo sustituidos, metódo para prepararlos y composiciones farmacéuticas que lo contienen.
MX336810B (es) Benzoxazepinonas fusionadas como moduladoras de canales ionicos.
CL2011002021A1 (es) Procedimiento de preparacion de una composicion enriquecida en compuestos fenolicos con una masa molecular inferior a 400 da, a partir de aguas de vegetacion de aceitunas, que comprende clarificacion de dichas aguas, ultrafiltracion tangencial de las aguas de vegetacion clarificadas, nanofiltracion del permeado, adsorcion de los compuestos fenolicos y concentracion.
BR112013023876A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
IN2015DN00017A (https=)
EA020330B3 (ru) Хиназолиновые соединения
BR112014018959A8 (pt) Compostos, composições farmacêuticas, utilizações de um composto e métodos para o tratamento do câncer
CU20130063A7 (es) Proceso de producción de depsipéptidos cíclicos
UY32704A (es) Compuestos de 2,3-dihidro-1h-indeno
UY32673A (es) Nuevas pirimidinas, composiciones farmaceuticas que las contienen, procedimientos de preparaciones y su aplicacion como medicamentos
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
PE20141264A1 (es) Procedimiento de obtencion de una composicion que contiene factores de crecimiento a partir de un compuesto sanguineo, y composicion obtenible por dicho procedimiento
MX2017004131A (es) Metodo y composicion para producir agentes regenerativos anti-inflamatorios/anti-catabolicos mejorados a partir de fluido fisiologico autologo.
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.

Legal Events

Date Code Title Description
FC Application refused